João Vicente da Silveira, Carine Sangaleti, Cleber Camacho, Ana Alice Wolf Maciel, Maria Claudia Irigoyen, Thiago Macedo, José Jayme G De Lima, Luciano F Drager, Luiz Aparecido Bortolotto, Heno Ferreira Lopes, Madson Q Almeida, Brent M Egan, Fernanda Marciano Consolim-Colombo
{"title":"预测难治性高血压患者原发性醛固酮增多症的醛固酮和醛固酮-肾素比值临界值:一项真实生活研究","authors":"João Vicente da Silveira, Carine Sangaleti, Cleber Camacho, Ana Alice Wolf Maciel, Maria Claudia Irigoyen, Thiago Macedo, José Jayme G De Lima, Luciano F Drager, Luiz Aparecido Bortolotto, Heno Ferreira Lopes, Madson Q Almeida, Brent M Egan, Fernanda Marciano Consolim-Colombo","doi":"10.3390/jcdd11100299","DOIUrl":null,"url":null,"abstract":"<p><p>Primary aldosteronism (PA) is commonly associated with resistant hypertension. Biochemical tests can be clinically useful in the screening and diagnosis of primary aldosteronism. This study aimed to identify the cutoff values of aldosterone levels (A) and the aldosterone-renin ratio (ARR) for an accurate prediction of PA in patients with apparent resistant hypertension in a real-life scenario. This database-based study included a historical cohort of male and female patients with apparent resistant hypertension, aged 18 years or older and surveyed for PA in a specialized center from 2008 to 2018. Aldosterone and plasma renin activity (PRA) or the plasma renin concentration (PRC) were measured in the treated hypertensive patients. The patients with positive screening results were subsequently referred to the endocrinology department for confirmatory tests. The patients with confirmed PA were included in the case group, and the others remained as controls. Receiver-operating characteristic (ROC) curves were used to identify the cutoff points for aldosterone and the ARR, thereby analyzing their sensitivity and specificity for confirmed PA. Among the 3464 patients (59 ± 13 years old, 41% male) who had apparent resistance hypertension screened, PA was confirmed in 276 individuals (8%). A ≥ 16.95 ng/dL (95% CI: 0.908-0.933) had an odds ratio of 6.24 for PA, while A/PRA ≥ 29.88 (95% CI: 0.942-0.984) or an A/PRC ≥ 2.44 (95% CI: 0.978-0.990) had an odds ratio of 216.17 for PA diagnoses. Our findings suggest that a positive PA screening with aldosterone ≥ 17 ng/dL associated with A/PRA ≥ 29.88 or an A/PRC ratio of ≥2.44 should be sufficient to confirm the diagnosis of PA without confirmatory testing.</p>","PeriodicalId":15197,"journal":{"name":"Journal of Cardiovascular Development and Disease","volume":"11 10","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11508297/pdf/","citationCount":"0","resultStr":"{\"title\":\"Cutoff Values of Aldosterone and the Aldosterone-Renin Ratio for Predicting Primary Aldosteronism in Patients with Resistant Hypertension: A Real-Life Study.\",\"authors\":\"João Vicente da Silveira, Carine Sangaleti, Cleber Camacho, Ana Alice Wolf Maciel, Maria Claudia Irigoyen, Thiago Macedo, José Jayme G De Lima, Luciano F Drager, Luiz Aparecido Bortolotto, Heno Ferreira Lopes, Madson Q Almeida, Brent M Egan, Fernanda Marciano Consolim-Colombo\",\"doi\":\"10.3390/jcdd11100299\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Primary aldosteronism (PA) is commonly associated with resistant hypertension. Biochemical tests can be clinically useful in the screening and diagnosis of primary aldosteronism. This study aimed to identify the cutoff values of aldosterone levels (A) and the aldosterone-renin ratio (ARR) for an accurate prediction of PA in patients with apparent resistant hypertension in a real-life scenario. This database-based study included a historical cohort of male and female patients with apparent resistant hypertension, aged 18 years or older and surveyed for PA in a specialized center from 2008 to 2018. Aldosterone and plasma renin activity (PRA) or the plasma renin concentration (PRC) were measured in the treated hypertensive patients. The patients with positive screening results were subsequently referred to the endocrinology department for confirmatory tests. The patients with confirmed PA were included in the case group, and the others remained as controls. Receiver-operating characteristic (ROC) curves were used to identify the cutoff points for aldosterone and the ARR, thereby analyzing their sensitivity and specificity for confirmed PA. Among the 3464 patients (59 ± 13 years old, 41% male) who had apparent resistance hypertension screened, PA was confirmed in 276 individuals (8%). A ≥ 16.95 ng/dL (95% CI: 0.908-0.933) had an odds ratio of 6.24 for PA, while A/PRA ≥ 29.88 (95% CI: 0.942-0.984) or an A/PRC ≥ 2.44 (95% CI: 0.978-0.990) had an odds ratio of 216.17 for PA diagnoses. Our findings suggest that a positive PA screening with aldosterone ≥ 17 ng/dL associated with A/PRA ≥ 29.88 or an A/PRC ratio of ≥2.44 should be sufficient to confirm the diagnosis of PA without confirmatory testing.</p>\",\"PeriodicalId\":15197,\"journal\":{\"name\":\"Journal of Cardiovascular Development and Disease\",\"volume\":\"11 10\",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11508297/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cardiovascular Development and Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/jcdd11100299\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Development and Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jcdd11100299","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
原发性醛固酮增多症(PA)通常与抵抗性高血压有关。生化检验可用于原发性醛固酮增多症的筛查和诊断。本研究旨在确定醛固酮水平(A)和醛固酮-肾素比值(ARR)的临界值,以便在现实生活中准确预测明显抵抗性高血压患者的醛固酮增多症。这项基于数据库的研究纳入了一个历史队列,其中包括年龄在18岁或18岁以上、2008年至2018年期间在一家专科中心接受过PA调查的明显抵抗性高血压男性和女性患者。在接受治疗的高血压患者中测量了醛固酮和血浆肾素活性(PRA)或血浆肾素浓度(PRC)。筛查结果呈阳性的患者随后被转至内分泌科进行确诊检查。确诊为 PA 的患者被纳入病例组,其他患者仍作为对照组。利用接收者工作特征曲线(ROC)确定醛固酮和 ARR 的临界点,从而分析其对确诊 PA 的敏感性和特异性。在 3464 名筛查出明显抵抗性高血压的患者(59 ± 13 岁,男性占 41%)中,有 276 人(8%)确诊为 PA。A/PRA≥16.95ng/dL(95% CI:0.908-0.933)与确诊 PA 的几率比为 6.24,而 A/PRA≥29.88(95% CI:0.942-0.984)或 A/PRC≥2.44 (95% CI:0.978-0.990)与确诊 PA 的几率比为 216.17。我们的研究结果表明,醛固酮≥ 17 ng/dL 且 A/PRA≥ 29.88 或 A/PRC 比值≥ 2.44 的 PA 筛查阳性结果应足以确诊 PA,而无需进行确证试验。
Cutoff Values of Aldosterone and the Aldosterone-Renin Ratio for Predicting Primary Aldosteronism in Patients with Resistant Hypertension: A Real-Life Study.
Primary aldosteronism (PA) is commonly associated with resistant hypertension. Biochemical tests can be clinically useful in the screening and diagnosis of primary aldosteronism. This study aimed to identify the cutoff values of aldosterone levels (A) and the aldosterone-renin ratio (ARR) for an accurate prediction of PA in patients with apparent resistant hypertension in a real-life scenario. This database-based study included a historical cohort of male and female patients with apparent resistant hypertension, aged 18 years or older and surveyed for PA in a specialized center from 2008 to 2018. Aldosterone and plasma renin activity (PRA) or the plasma renin concentration (PRC) were measured in the treated hypertensive patients. The patients with positive screening results were subsequently referred to the endocrinology department for confirmatory tests. The patients with confirmed PA were included in the case group, and the others remained as controls. Receiver-operating characteristic (ROC) curves were used to identify the cutoff points for aldosterone and the ARR, thereby analyzing their sensitivity and specificity for confirmed PA. Among the 3464 patients (59 ± 13 years old, 41% male) who had apparent resistance hypertension screened, PA was confirmed in 276 individuals (8%). A ≥ 16.95 ng/dL (95% CI: 0.908-0.933) had an odds ratio of 6.24 for PA, while A/PRA ≥ 29.88 (95% CI: 0.942-0.984) or an A/PRC ≥ 2.44 (95% CI: 0.978-0.990) had an odds ratio of 216.17 for PA diagnoses. Our findings suggest that a positive PA screening with aldosterone ≥ 17 ng/dL associated with A/PRA ≥ 29.88 or an A/PRC ratio of ≥2.44 should be sufficient to confirm the diagnosis of PA without confirmatory testing.